儿童Graves病的放射性碘治疗:一项多中心回顾性研究
该多中心回顾性队列研究纳入69例接受I-131治疗的儿童Graves病患者,甲状腺体积由超声测量,平均给药活度为12.5 mCi(463 MBq)。6个月时80.5%的患者甲状腺功能减退,11.9%甲状腺功能正常;6个月时仍甲状腺功能亢进者按甲状腺体积和24小时摄取率校正的给药活度较低(0.18 vs 0.31 mCi×%/mL,P=0.0054)。作者认为需将给药活度标准化,并建议≥0.25 mCi(9.3 MBq)×%/mL甲状腺组织。
要点
- 儿童Graves病I-131治疗给药活度差异大,平均12.5 mCi(463 MBq),范围3.8-29.9 mCi。
- 6个月时80.5%甲减、11.9%甲功正常;6个月仍甲亢者校正给药活度较低(0.18 vs 0.31 mCi×%/mL,P=0.0054)。
- 作者建议按超声甲状腺体积和24小时摄取率校正,给药活度≥0.25 mCi(9.3 MBq)×%/mL。
核心结论
- 儿童Graves病I-131治疗给药活度差异大;6个月仍甲亢者按甲状腺体积和24小时摄取率校正的给药活度较低(0.18 vs 0.31 mCi×%/mL,P=0.0054);作者建议给药活度≥0.25 mCi(9.3 MBq)×%/mL甲状腺组织。
研究设计与样本
- 回顾性队列研究,3家机构,纳入2004年11月至2019年10月接受I-131治疗的69例18岁以下Graves病患儿,甲状腺体积由超声测量,比较采用Mann-Whitney U检验。
诊断标准与关键数值
- 6个月时67例中54例(80.5%)甲减、8例(11.9%)甲功正常、5例甲亢;12个月时5例甲亢中2例转为甲功正常,1例原甲功正常者转为甲亢;6个月仍甲亢者校正给药活度0.18 mCi(6.7 MBq)×%/mL vs 0.31 mCi(11.5 MBq)×%/mL,P=0.0054。
临床应用与阅片要点
- 作者认为需将给药活度标准化,建议以超声测量的甲状腺体积和24小时摄取率校正,给药活度≥0.25 mCi(9.3 MBq)×%/mL甲状腺组织。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: There is no standardized approach to iodine-131 (I-131) therapy of hyperthyroidism in pediatric Graves disease. This prevents systematic study of outcomes.
OBJECTIVE: To characterize current radioiodine dosing and define therapeutic outcomes at multiple institutions that use ultrasound to measure thyroid size to guide I-131 ablation of Graves disease.
MATERIALS AND METHODS: This was a retrospective cohort study conducted at three institutions. The three sites collected demographic data, thyroid volume measured by ultrasound (mL), pre-ablation radioiodine uptake, I-131 activity administered, and outcomes at 6 and 12 months for children younger than 18 years of age treated with I-131 between November 2004 and October 2019. Comparisons of continuous variables were performed using the Mann-Whitney U test.
RESULTS: Sixty-nine patients (mean age: 14.5±2.5 years) were included, 59 (85.5%) of whom were female. The mean administered I-131 radioiodine activity was 12.5 mCi (463 MBq) (range: 3.8-29.9 mCi [141-1,106 MBq]). At 6 months post-ablation, 54 (80.5% of 67) patients were hypothyroid, 8 (11.9% of 67) were euthyroid and 5 were hyperthyroid. Two of the five hyperthyroid patients had become euthyroid at 12 months. At 12 months, 1 previously euthyroid patient was hyperthyroid. Administered activity per mL of thyroid tissue adjusted for 24-h uptake was lower (0.18 mCi [6.7 MBq] x %/mL vs. 0.31 mCi [11.5 MBq] x %/mL, P=0.0054) for patients who remained hyperthyroid at 6 months.
CONCLUSION: There is substantial variability in administered activity for radioiodine ablation of Graves disease in children. Efforts to standardize practice should start by standardizing administered activity guided by measurement of thyroid size by ultrasound. Our results and those of previous studies suggest the need for administered activities ≥0.25 mCi [9.3 MBq] x %/mL of thyroid tissue.
引用
- Trout, Khalatbari, Shogbesan, et al. Radioiodine treatment of pediatric Graves disease: a multicenter review. Pediatr Radiol. 2022. PMID: 35750940. doi:10.1007/s00247-022-05415-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。